Ankylosing Spondylitis

The FDA has approved a citrate-free, 100 mg/mL formulation of the Humira biosimilar Hadlima, according to a statement released by Samsung Bioepis and Organon.

Patients with ankylosing spondylitis who exhibit depression and hypertension appear to demonstrate worse function and disease activity, according to data presented at EULAR 2022 Congress.

Interventions to prevent lumbar and thoracic movement restriction in patients with ankylosing spondylitis may require early intervention, as degradation seems to mainly occur in the first years of disease progression, a study found.

A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease, according to data.

This month’s cover story is a roundtable discussing the coordination of care for patients with both ankylosing spondylitis and inflammatory bowel disease, and features commentary from gastroenterologists and rheumatologists, including Miguel Regueiro, MD; Brett Smith, DO; Ashwin N. Ananthakrishnan, MD, MPH, MBBS; Nicole Cotter, MD; Sharon Dudley-Brown, PhD, FNP-BC; and Seyedehsan Navabi, MD. It is a terrific read and reminded me of one of the many reasons that rheumatology is such a terrific specialty — namely, that we have virtually no boundaries.

Sometimes, the best way to care for a patient is to know one’s own limitations.

The FDA has approved once-daily oral upadacitinib for the treatment of adults with active ankylosing spondylitis who are intolerant, or have had an inadequate response, to one or more TNF inhibitors.

Acute anterior uveitis in first-degree relatives of axial spondyloarthritis probands should trigger a screening for axial SpA, according to researchers in the Annals of the Rheumatic Diseases.

Patients with psoriatic arthritis or ankylosing spondylitis who received once daily upadacitinib 15 mg experienced improvements in pain measures through 1 year, according to data published in RMD Open.

Nonradiographic axial spondyloarthritis remains an underrecognized and undertreated condition in the United States, with rheumatology often the last stop for many of these patients. However, with a recent ICD-10 code upgrade, that may begin to change.